Last reviewed · How we verify
TRC105 chimeric anti-CD105 antibody
At a glance
| Generic name | TRC105 chimeric anti-CD105 antibody |
|---|---|
| Sponsor | Tracon Pharmaceuticals Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Fatigue
- Hyponatremia
- Hypertension
- Anemia
- Hypoalbuminemia
- Headache
- Alkaline phosphatase increased
- Aspartate aminotransferase increased
- Alanine aminotransferase increased
- Platelet count decreased
- Anorexia
- Proteinuria
Key clinical trials
- Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer (PHASE2)
- Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme (PHASE1, PHASE2)
- TRC105 for Liver Cancer That Has Not Responded to Sorafenib (PHASE2)
- Open Label Phase 1 Dose Finding Study of TRC105 in Patients With Solid Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TRC105 chimeric anti-CD105 antibody CI brief — competitive landscape report
- TRC105 chimeric anti-CD105 antibody updates RSS · CI watch RSS
- Tracon Pharmaceuticals Inc. portfolio CI